1. Home
  2. ARHS vs INBX Comparison

ARHS vs INBX Comparison

Compare ARHS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arhaus Inc.

ARHS

Arhaus Inc.

HOLD

Current Price

$5.73

Market Cap

956.8M

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$111.28

Market Cap

999.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARHS
INBX
Founded
1986
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
956.8M
999.7M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
ARHS
INBX
Price
$5.73
$111.28
Analyst Decision
Buy
Buy
Analyst Count
9
3
Target Price
$10.78
$150.00
AVG Volume (30 Days)
1.3M
586.3K
Earning Date
05-07-2026
05-15-2026
Dividend Yield
4.78%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$1,379,222,000.00
$1,300,000.00
Revenue This Year
$7.23
N/A
Revenue Next Year
$7.10
N/A
P/E Ratio
$293.00
N/A
Revenue Growth
8.51
550.00
52 Week Low
$5.63
$12.80
52 Week High
$12.97
$155.29

Technical Indicators

Market Signals
Indicator
ARHS
INBX
Relative Strength Index (RSI) 29.88 50.41
Support Level N/A $69.30
Resistance Level $7.62 $155.29
Average True Range (ATR) 0.35 13.20
MACD -0.18 -3.55
Stochastic Oscillator 3.25 23.22

Price Performance

Historical Comparison
ARHS
INBX

About ARHS Arhaus Inc.

Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: